The effect of thalidomide on experimental tumors and metastases

Anti-Cancer Drugs

Volumn 7, Issue 3, 1996, Pages 339-343

  Minchinton, Andrew I ^a,b   Fryer, Karen H ^a   Wendt, Karen R ^a   Clow, Kathy A ^a   Hayes, Malcolm M M ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Anti angiogenesis; Lewis Lung; metastasis; Neovascularization; Radiation; SCCVII; Thalidomide; Tumor oxygenation

Indexed keywords

THALIDOMIDE; TIRAPAZAMINE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HYPOXIA; INTRAPERITONEAL DRUG ADMINISTRATION; LEWIS CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA;

EID: 0029941264     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199605000-00015     Document Type: Article

References (18)

1. Lenz W, Knapp K. Thalidomide embryopathy. Dt med Wischr 1962; 87: 1232-42.
2. McBride WC. Thalidomide and congenital abnormalities. Lancet 196l; ii: 1358.
3. D'Amato RJ, Loughnan MS, Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sei USA 1994; 91: 4082-5.
4. Folkman J. Tumor angiogenesis. Adu Cancer Res 1985; 43: 175-203.
5. Bicknell R, Harris AL. Anticancer strategies involving the vasculature: vascular targeting and the inhibition of angiogenesis. Semin Cancer Biol 1992; 3: 399-407.
6. Denekamp J, Hill S. Angiogenic attack as a therapeutic strategy for cancer. Radiother Oncol 1991; 20: 103-12.
7. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Bio! 1992; 3: 89-96.
8. Brown J M. SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumors. Br J Cancer 1993; 67: 1163-70.
9. Adams, GE, Stratford IJ. Bioreductive drugs for cancer therapy: the search for tumor specificity. Int J Radiat Oncol Biol Pbys 1994; 29: 231-8.
10. Minchinton AI, Brown JM. Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing. Br J Cancer 1992; 66: 1053-8.
11. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6: 303-6.
12. lyer CG, Languillon J, Ramanujam K, et al. WHO coordinated short- term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull WHO 1971; 45: 719-32.
13. Barnhill RL, McDougall AC. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. / Am Acad Dermatol 1982; 7: 317-23.
14. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O. Treatment of refractory rheumatoid arthritis-the thalidomide experience. J Rheumatol 1989; 16: 158-63.
15. Makonkawkeyoon S, Limson-Pobre RN, Moreira AL, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc A'atl Acad Sei USA 1993; 90: 5974-8.
16. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32: 866-9.
17. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. New Eng J Med 1992; 326: 1055-8.
18. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [see comments]. Cell 1994; 79- 315-28.